ID   K562-R
AC   CVCL_B0FH
DR   Wikidata; Q108820617
RX   PubMed=2568171;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 29-06-23; Version: 5
//
RX   PubMed=2568171;
RA   Yanovich S., Hall R.E., Gewirtz D.A.;
RT   "Characterization of a K562 multidrug-resistant cell line.";
RL   Cancer Res. 49:4499-4503(1989).
//